https://www.nasdaq.com/press-release/aytu-biopharma-appoints-mark-oki-as-chief-financial-officer-2022-01-04
https://www.nasdaq.com/press-release/aytu-biopharma-to-present-at-h.c.-wainwright-bioconnect-conference-2022-01-03
https://www.nasdaq.com/press-release/denovo-biopharma-llc-announces-partner-aytu-biopharma-receives-fda-clearance-and
https://www.nasdaq.com/press-release/aytu-biopharma-announces-fda-clearance-of-investigational-new-drug-ind-application
https://www.nasdaq.com/press-release/aytu-biopharma-receives-orphan-drug-designation-from-fda-for-ar101-for-treatment-of
https://www.nasdaq.com/press-release/aytu-biopharma-announces-issuance-of-first-u.s.-patent-supporting-healight
https://www.nasdaq.com/press-release/aytu-biopharma-ranked-number-178-fastest-growing-company-in-north-america-on-the-2021
https://www.nasdaq.com/press-release/aytu-biopharma-reports-first-quarter-2022-financial-results-2021-11-15
https://www.nasdaq.com/press-release/aytu-biopharma-to-report-first-quarter-fiscal-2022-results-and-provide-business
https://www.nasdaq.com/press-release/correction%3a-aytu-biopharma-to-present-at-upcoming-september-investor-conferences-2021
https://www.nasdaq.com/press-release/aytu-biopharma-reports-fourth-quarter-and-full-year-fiscal-2021-financial-results
https://www.nasdaq.com/press-release/aytu-biopharma-to-report-fourth-quarter-and-full-year-fiscal-2021-results-and-provide
https://www.nasdaq.com/press-release/aytu-biopharma-announces-formation-of-new-scientific-advisory-board-to-support
https://www.nasdaq.com/press-release/aytu-biopharma-to-present-at-upcoming-september-investor-conferences-2021-09-07
https://www.nasdaq.com/press-release/aytu-biopharma-announces-publication-of-data-demonstrating-ultraviolet-a-light
https://www.nasdaq.com/press-release/aytu-biopharma-announces-peer-reviewed-publication-of-clinical-results-from
https://www.nasdaq.com/press-release/aytu-biopharma-to-present-at-upcoming-june-investor-conferences-2021-05-25
https://www.nasdaq.com/press-release/aytu-biopharma-reports-fiscal-third-quarter-2021-financial-results-and-recent
https://www.nasdaq.com/press-release/aytu-biopharma-announces-publication-of-in-vitro-study-demonstrating-that-ultraviolet
https://www.nasdaq.com/press-release/aytu-biopharma-to-report-third-quarter-fiscal-2021-results-on-may-17-2021-2021-05-12
https://www.nasdaq.com/press-release/aytu-biopharma-adds-late-stage-pediatric-onset-rare-disease-asset-to-development
https://www.nasdaq.com/press-release/aytu-biopharma-strengthens-leadership-team-with-appointment-of-richard-eisenstadt-as
https://www.nasdaq.com/press-release/aytu-biopharma-divests-u.s.-rights-to-natestor-to-acerus-pharma-2021-04-01
https://www.nasdaq.com/press-release/aytu-bioscience-announces-close-of-merger-with-neos-therapeutics-2021-03-22
https://www.nasdaq.com/press-release/aytu-bioscience-announces-positive-clinical-results-from-healighttm-pilot-study-in
https://www.nasdaq.com/press-release/aytu-bioscience-to-present-at-upcoming-march-investor-conferences-2021-02-24
https://www.nasdaq.com/press-release/aytu-bioscience-announces-record-fiscal-q2-2021-net-revenue-of-%2415.1-million-an
https://www.nasdaq.com/press-release/aytu-bioscience-and-neos-therapeutics-announce-special-meetings-of-stockholders-0
https://www.nasdaq.com/press-release/aytu-bioscience-and-neos-therapeutics-announce-special-meetings-of-stockholders
https://www.nasdaq.com/press-release/aytu-bioscience-to-report-second-fiscal-2021-results-and-provide-business-update-on
https://www.nasdaq.com/press-release/aytu-bioscience-announces-completion-of-healighttm-safety-study-in-critically-ill
https://www.nasdaq.com/press-release/aytu-bioscience-announces-closing-of-%2428.75-million-bought-deal-offering-and-full
https://www.nasdaq.com/press-release/aytu-bioscience-to-present-at-the-ld-micro-virtual-investor-conference-on-tuesday
https://www.nasdaq.com/press-release/aytu-bioscience-increases-previously-announced-bought-deal-offering-to-%2425.0-million
https://www.nasdaq.com/press-release/aytu-bioscience-announces-%2410.0-million-bought-deal-offering-2020-12-10
https://www.nasdaq.com/press-release/aytu-bioscience-and-neos-therapeutics-announce-definitive-merger-agreement-creating-a
https://www.nasdaq.com/press-release/aytu-bioscience-and-neos-therapeutics-announce-definitive-merger-agreement-creating-0
https://www.nasdaq.com/press-release/aytu-bioscience-announces-fiscal-q1-2021-net-revenue-of-%2413.5-million-an-increase-of
https://www.nasdaq.com/press-release/aytu-bioscience-to-present-at-the-jefferies-2020-virtual-london-healthcare-conference
https://www.nasdaq.com/press-release/aytu-bioscience-to-report-first-quarter-fiscal-2021-results-and-provide-business
https://www.nasdaq.com/press-release/aytu-bioscience-announces-fiscal-q4-2020-net-revenue-of-%2414.9-million-an-increase-of
https://www.nasdaq.com/press-release/aytu-bioscience-to-report-fourth-quarter-and-full-year-fiscal-2020-results-and
https://www.nasdaq.com/press-release/aytu-bioscience-to-reschedule-fourth-quarter-and-fy-2020-conference-call-2020-09-23
https://www.nasdaq.com/press-release/aytu-bioscience-to-report-fourth-quarter-fy-2020-results-and-business-update-on
https://www.nasdaq.com/press-release/aytu-bioscience-announces-global-agreement-to-distribute-pinnacle-ivd-corporations-15
https://www.nasdaq.com/press-release/aytu-bioscience-announces-launch-of-nationwide-mobile-covid-19-testing-initiative
https://www.nasdaq.com/press-release/aytu-bioscience-announces-manufacture-and-delivery-of-healighttm-devices-for-use-in
https://www.nasdaq.com/press-release/ld-micro-announces-preliminary-list-of-presenters-for-the-ld-500-2020-08-05
https://www.nasdaq.com/press-release/aytu-bioscience-announces-regulatory-approval-of-zolpimistr-by-australian-therapeutic
https://www.nasdaq.com/press-release/covid-19-igg-igm-rapid-test-cassette-distributed-by-aytu-bioscience-featured-in
https://www.nasdaq.com/press-release/aytu-bioscience-announces-expansion-of-natestor-u.s.-commercial-team-2020-07-20
https://www.nasdaq.com/press-release/aytu-bioscience-announces-distribution-partnership-with-apollo-med-innovations-to
https://www.nasdaq.com/press-release/aytu-bioscience-announces-results-from-a-national-cancer-institute-evaluation-of-the
https://www.nasdaq.com/press-release/aytu-bioscience-set-to-join-russell-3000r-index-2020-06-08
https://www.nasdaq.com/press-release/aytu-bioscience-announces-significant-improvement-in-natestor-patient-access-in-the
https://www.nasdaq.com/press-release/aytu-bioscience-announces-%2415-million-debt-retirement-2020-06-01
https://www.nasdaq.com/press-release/aytu-bioscience-announces-emergency-use-authorization-of-covid-19-igg-igm-rapid-test
https://www.nasdaq.com/press-release/aytu-bioscience-reports-third-quarter-fiscal-2020-financial-results-2020-05-14
https://www.nasdaq.com/press-release/aytu-bioscience-to-report-fiscal-q3-fy-2020-results-and-business-update-2020-05-07
https://www.nasdaq.com/press-release/aytu-bioscience-announces-china-export-clearance-of-companys-covid-19-igg-igm-rapid
https://www.nasdaq.com/press-release/aytu-bioscience-signs-development-agreement-with-sterling-medical-devices-to-advance
https://www.nasdaq.com/press-release/aytu-bioscience-announces-results-from-annual-stockholders-meeting-2020-04-24
https://www.nasdaq.com/press-release/aytu-bioscience-announces-exclusive-distribution-agreement-for-covid-19-igg-igm-rapid
https://www.nasdaq.com/press-release/aytu-bioscience-announces-publication-of-results-from-natesto-spermatogenesis-study
https://www.nasdaq.com/press-release/aytu-bioscience-signs-exclusive-global-license-with-cedars-sinai-for-potential
https://www.nasdaq.com/press-release/aytu-bioscience-confirms-export-and-incoming-delivery-of-covid-19-igg-igm-rapid-tests
https://www.nasdaq.com/press-release/aytu-bioscience-announces-positive-results-from-an-independently-conducted-clinical
https://www.nasdaq.com/press-release/aytu-bioscience-provides-update-on-its-licensed-covid-19-igg-igm-rapid-test-supply
https://www.nasdaq.com/press-release/aytu-bioscience-consumer-health-subsidiary-launches-regoxidiner-an-fda-approved-hair
https://www.nasdaq.com/press-release/aytu-bioscience-announces-updated-annual-shareholder-meeting-date-and-virtual-room
https://www.nasdaq.com/press-release/aytu-bioscience-announces-exclusive-zolpimisttm-license-to-commercialize-aytus-oral
https://www.nasdaq.com/press-release/aytu-bioscience-receives-%2423.0-million-from-warrant-exercises-2020-04-07
https://www.nasdaq.com/press-release/aytu-featured-on-nbc-and-fox-news-video%3a-denver-officers-firefighters-will-be-among
https://www.nasdaq.com/press-release/aytu-bioscience-announces-first-commercial-shipment-of-its-2-10-minute-covid-19-igg
https://www.nasdaq.com/press-release/aytu-bioscience-announces-receipt-of-initial-shipment-of-100000-covid-19-igg-igm
https://www.nasdaq.com/press-release/aytu-announces-delay-of-annual-meeting-of-stockholders-due-to-colorados-shelter-in
https://www.nasdaq.com/press-release/aytu-bioscience-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2020-03
https://www.nasdaq.com/press-release/aytu-bioscience-submits-notice-of-commercialization-to-the-fda-allowing-for-companys
https://www.nasdaq.com/press-release/aytu-announces-%2420-million-registered-direct-offering-priced-at-the-market-2020-03-19
https://www.nasdaq.com/press-release/aytu-bioscience-expands-its-distribution-rights-for-coronavirus-2019-covid-19-point
https://www.nasdaq.com/press-release/aytu-bioscience-announces-acceleration-of-u.s.-availability-of-covid-19-igg-igm-rapid
https://www.nasdaq.com/press-release/aytu-biosciences-coronavirus-rapid-test-featured-on-nbc-and-fox-news-videos%3a
https://www.nasdaq.com/press-release/aytu-bioscience-establishes-covid-19-igg-igm-rapid-test-product-inquiry-procedure-for
https://www.nasdaq.com/press-release/aytu-announces-%2420-million-registered-direct-offering-priced-at-the-market-2020-03-12
https://www.nasdaq.com/press-release/aytu-announces-%249.0-million-registered-direct-offering-priced-at-the-market-2020-03
https://www.nasdaq.com/press-release/aytu-bioscience-secures-exclusive-u.s.-distribution-agreement-for-coronavirus-2019
https://www.nasdaq.com/press-release/aytu-bioscience-completes-acquisition-of-innovus-pharmaceuticals-2020-02-18
https://www.nasdaq.com/press-release/aytu-reports-q2-revenue-of-%243.2m-up-77-year-over-year-and-121-sequentially-2020-02-13
https://www.nasdaq.com/press-release/aytu-bioscience-to-report-fiscal-q2-fy-2020-results-and-business-update-2020-02-06
https://www.nasdaq.com/press-release/aytu-bioscience-announces-acceptance-of-results-of-two-natesto-clinical-studies-for
https://www.nasdaq.com/press-release/aytu-bioscience-announces-acceptance-of-natesto-spermatogenesis-study-results-for
https://www.nasdaq.com/press-release/aytu-bioscience-and-innovus-pharmaceuticals-announce-effectiveness-of-form-s-4
https://www.nasdaq.com/press-release/aytu-bioscience-and-innovus-pharmaceuticals-announce-filing-of-form-s-4-registration
https://www.nasdaq.com/press-release/shareholder-alert%3a-monteverde-associates-pc-announces-an-investigation-regarding-1
https://www.nasdaq.com/press-release/mioxsys-male-infertility-test-will-be-featured-in-product-symposium-at-the-8th-annual
https://www.nasdaq.com/press-release/aytu-bioscience-to-present-at-ld-micro-12th-annual-main-event-investor-conference-on
https://www.nasdaq.com/press-release/aytu-bioscience-announces-launch-of-natestor-u.s.-co-promotion-with-acerus
https://www.nasdaq.com/press-release/aytu-bioscience-announces-addition-of-tuzistrar-xr-to-leading-pharmacy-benefit
https://www.nasdaq.com/press-release/aytu-reports-first-quarter-2020-financial-results-2019-11-14
https://www.nasdaq.com/press-release/aytu-bioscience-announces-hiring-of-matthew-phillips-as-executive-vice-president-of
https://www.nasdaq.com/press-release/aytu-bioscience-to-report-fiscal-q1-fy-2020-results-and-business-update-2019-11-07
https://www.nasdaq.com/press-release/aytu-bioscience-announces-closing-of-%2412.4m-prescription-product-portfolio-purchase
https://www.nasdaq.com/press-release/aytu-bioscience-announces-addition-of-tuzistrar-xr-to-leading-national-pharmacy
https://www.nasdaq.com/press-release/aytu-bioscience-announces-positive-clinical-results-from-natestor-spermatogenesis
https://www.nasdaq.com/press-release/aytu-bioscience-to-announce-results-from-natestor-spermatogenesis-study-on-thursday
https://www.nasdaq.com/press-release/aytu-bioscience-acquires-%2412.4-million-prescription-product-portfolio-2019-10-14
https://www.nasdaq.com/press-release/aytu-bioscience-announces-%2410-million-private-placement-2019-10-14
https://www.nasdaq.com/press-release/aytu-bioscience-and-validus-pharmaceuticals-announce-zolpimist-co-promotion-agreement
https://www.nasdaq.com/press-release/aytu-bioscience-reports-100-revenue-growth-to-%247.3-million-in-fy-2019-2019-09-26
https://www.nasdaq.com/press-release/aytu-bioscience-announces-addition-of-natestor-to-leading-national-pharmacy-benefit
https://www.nasdaq.com/press-release/aytu-bioscience-to-report-fiscal-fy-2019-results-and-business-update-2019-09-19
https://www.nasdaq.com/press-release/aytu-bioscience-to-present-at-ladenburg-thalmann-2019-healthcare-conference-2019-09
